Literature DB >> 15809050

Enhanced v-Src-induced oncogenic transformation in the absence of focal adhesion kinase is mediated by phosphatidylinositol 3-kinase.

Konstadinos Moissoglu1, Sanjay Sachdev, Irwin H Gelman.   

Abstract

We showed previously [K. Moissoglu, I.H. Gelman, J. Biol. Chem. 278 (2003) 47946-47959] that oncogenic v-Src could induce 7- to 10-fold greater anchorage-independent growth (AIG) in FAK-null mouse embryo fibroblasts (MEF) compared to those expressing FAK. Here, we demonstrate that the enhanced AIG (eAIG) correlates with increased activation levels of phosphatidylinositol 3-kinase (PI3K) and not with changes in the protein levels of the p85 regulatory subunit of PI3K, PDK1 or PTEN- modulators, and/or mediators of PI3K activity. eAIG could be blunted selectively by treatment with the PI3K inhibitor, LY294002, or by overexpression of either the PI3K antagonist, PTEN, dominant-interfering alleles of PI3K or a downstream PI3K mediator, AKT, but not by the MEK inhibitor, PD98059, dominant-interfering alleles of MEK or the signal transducer and activator of transcription (STAT)-3. In contrast, RNAi-mediated knockdown of FAK resulted in increased v-Src-induced AIG. Expression of a constitutively active PI3K allele was sufficient to induce higher levels of AIG, whereas overexpression of v-Src produced only larger-sized colonies in soft agar. Interestingly, FAK was required for full activation of PI3K by PDGF whereas the activation of PI3K by insulin was significantly increased in FAK-/- cells. Thus, although FAK is dispensable for v-Src-induced oncogenic transformation in vitro, it may exert either positive or negative effects on signaling or motility depending on which pathways are activated in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809050     DOI: 10.1016/j.bbrc.2005.03.025

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12.

Authors:  Shin Akakura; Peter Nochajski; Lingqiu Gao; Paula Sotomayor; Sei-ichi Matsui; Irwin H Gelman
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

2.  Cross-Phosphorylation and Interaction between Src/FAK and MAPKAP5/PRAK in Early Focal Adhesions Controls Cell Motility.

Authors:  Sheila Figel Dwyer; Irwin H Gelman
Journal:  J Cancer Biol Res       Date:  2014-05-14

3.  Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.

Authors:  Frank Aboubakar Nana; Marylène Lecocq; Maha Zohra Ladjemi; Bruno Detry; Sébastien Dupasquier; Olivier Feron; Pierre P Massion; Yves Sibille; Charles Pilette; Sebahat Ocak
Journal:  Mol Cancer Ther       Date:  2018-10-23       Impact factor: 6.261

4.  Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells.

Authors:  Ji Yeon Lee; Man Hee Rhee; Jae Youl Cho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-26       Impact factor: 3.000

5.  Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.

Authors:  Sanjay Sachdev; Yahao Bu; Irwin H Gelman
Journal:  BMC Cancer       Date:  2009-01-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.